September 26, 2024
Emergent BioSolutions Secures $400 Million in Orders for Smallpox and Mpox Vaccines Amid Ongoing Outbreak
Emergent BioSolutions, smallpox, mpox, vaccine orders, biodefense, global health preparedness
Transforming Multiple Sclerosis Treatment: Emerging Trends and Future Directions
Multiple sclerosis, high-efficacy treatments, stem cell transplantation, disease-modifying therapies, personalized medicine, AI integration, myelin repair, neurorestorative therapies.
Pfizer Withdraws Sickle Cell Disease Treatment Oxbryta Globally Due to Safety Concerns
Pfizer, Oxbryta, sickle cell disease, global market withdrawal, safety concerns, clinical trials, vaso-occlusive crises, fatal events
Novo Nordisk’s Ozempic Expected to Face Medicare Price Negotiations in 2025
Ozempic, Medicare, price negotiations, Novo Nordisk, diabetes medication, Inflation Reduction Act
Sanofi Receives Bids from Private Equity Firms for $16B+ Consumer Health Business
Sanofi, private equity firms, consumer health business, PAI Partners, Clayton, Dubilier & Rice, Bloomberg
Merck’s Keytruda and LAG-3 Antibody Combo Fails in Phase 3 Colorectal Cancer Trial
Keytruda, LAG-3, colorectal cancer, Phase 3 trial, Merck & Co., favezelimab, pembrolizumab, KEYFORM-007
FDA Approves IntraBio’s Aqneursa for Niemann-Pick Disease Type C, Marking Second Approval in a Week
IntraBio, Aqneursa, Niemann-Pick disease type C, FDA approval, rare neurodegenerative disease, levacetylleucine
Amgen’s Mixed Results: A Tale of Two Readouts in Eczema and Myasthenia Gravis Trials
Amgen, Clinical Trials, Eczema, Myasthenia Gravis, Rocatinlimab, Uplizna, Biotechnology, Pharmaceutical Industry